SCHEMBL9917029

SCHEMBL9917029

CN1CCC2(CCC2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10176812 0.94 USP2 (0.50)
SCHEMBL8239021 0.92 USP2 (0.48)
SCHEMBL19199543 0.92 USP2 (0.48)
SCHEMBL1753496 0.90 USP2 (0.56)
SCHEMBL9966035 0.89 USP2 (0.55)
SCHEMBL1753491 0.88 USP2 (0.44)
SCHEMBL4547459 0.88
SCHEMBL20201099 0.86 USP2 (0.48)
SCHEMBL1753469 0.86 USP2 (0.53)
SCHEMBL1753720 0.85 CYP3A4 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4393916-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-07-03 EP disclosed
EP-3863638-B1 PHOSPHODIESTERASE INHIBITORS UNIV NEBRASKA (US) 2024-06-26 EP disclosed
WO-2023239629-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE CDK2 Plexium, Inc. (US) 2023-12-14 WO disclosed
US-20230331722-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-10-19 US disclosed
WO-2023196720-A2 LRRK2 INHIBITORS Brenig Therapeutics, Inc. (US) 2023-10-12 WO disclosed
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF BRIDGENE BIOSCIENCES, INC. 2023-09-14 US disclosed
US-20230250096-A1 SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-08-10 US disclosed
US-20230250096-A1 SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-08-10 US disclosed
US-20140179638-A1 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS KBP BIOSCIENCES CO., LTD. (CN) 2014-06-26 US disclosed
US-20140161801-A1 QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Xuanzhu Pharma Co., Ltd. (CN) 2014-06-12 US disclosed
EP-2735567-A1 HETEROCYCLIC SUBSTITUTED PYRIMIDINE COMPOUND Xuanzhu Pharma Co., Ltd. (CN) 2014-05-28 EP disclosed
US-20130131132-A1 N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBVIE INC. (US) 2013-05-23 US disclosed
WO-2013010382-A1 HETEROCYCLIC SUBSTITUTED PYRIMIDINE COMPOUND 山东亨利医药科技有限责任公司 (CN) 2013-01-24 WO disclosed
US-20120214782-A1 New compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-23 US disclosed
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-23 US disclosed
US-20120149698-A1 NOUVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-14 US disclosed
US-20110195954-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-11 US disclosed
WO-2007098962-A1 SIGMA RECEPTOR COMPOUNDS LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2007-09-07 WO disclosed